

ThromboGenics Promoted to the NEXT 150 Index

Strong Share Price Performance Key Driver in Inclusion

Leuven, Belgium – 30 June, 2009 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the Company has been promoted to the NEXT 150 index on the Euronext stock exchange.

ThromboGenics' inclusion in the NEXT 150 index reflects the strong share price performance and progress that the Company continues to make. The inclusion of the Company in the NEXT 150 index also follows the Company entering the VLAM-21 index earlier in the year, which is a capitalized-weighted index of the 21 most capitalized Flemish stocks that are traded on a stock exchange.

The NEXT 150 index comprises mid to large capitalisation stocks on the Euronext exchange. The index consists of the 150 next largest stocks following the Euronext 100 index and includes stocks from the Amsterdam, Brussels, Lisbon and Paris exchanges of Euronext.

ThromboGenics will be included in the NEXT 150 index as of July 1st, 2009.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to be included in the NEXT 150 index which reflects the tremendous progress ThromboGenics has made since its inception. The inclusion in the index will further increase the Company's access to a wide pool of investors and enhance ThromboGenics' strong profile as one of the leading biotechnology companies in Europe."

-Ends-

For further information please contact:

ThromboGenics

Dr. Patrik De Haes, CEO

Tel: + 32 16 75 13 10
patrik.dehaes@thrombogenics.com

Chris Buyse, CFO

Tel : + 32 16 75 13 10
chris.buyse@thrombogenics.com

Citigate Dewe Rogerson

Amber Bielecka/ David Dible/ Nina Enegren

Tel: +44 (0) 207 638 95 71
amber.bielecka@citigatedr.co.uk



About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.